Global RNA-Targeted Novel Drug Modalities Market Analysis Report 2022: Landscape Analysis of Technologies, Targets, Business and Financing from An Industry Perspective
This report provides you with a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective.
The report evaluates the partnering deals of pharmaceutical companies with RNA-targeted drug discovery companies regarding scope of the agreement and economic terms which allows to identify preferences of major pharmaceutical companies for RNA-targeted novel drug modalities.
Over the past several years, the pharmaceutical industry has increased its efforts to identify novel drug targets outside of the usual G protein-coupled receptors, ion channels, and enzymes of multiple families, including kinases, in order to provide a greater variety of therapeutic options for patient populations across a number of disease states. In this context, recent attention has turned to looking for regulators of RNA function, including small molecules and biologics.
Previously considered "difficult to drug" on a structural and selectivity basis, considerable efforts in academia and industry are now being focused on targeting RNA as a therapeutic modality. These efforts are driven based on both the biological significance of RNAs, as well as a growing number of studies implicating aberrant RNA biology in many human diseases.
RNAs mediate cellular processes such as the regulation of gene transcription, splicing and the enhancement or inhibition of protein activity. Not surprisingly, based on the myriad important functions of cellular RNAs, their dysregulation is often associated with disease phenotypes and RNA molecules are increasingly recognized as potential targets for drug development efforts.
Small-molecule- and oligonucleotide-based therapies are being pursued toward the goal of targeting RNA biology. This broad range of approaches, which also includes the targeting of RNAs and RNA-binding proteins and RNA-modifying enzymes, is in line with the known complexity of RNA biology and regulation.
Although it is now recognized that many RNAs can adopt complex tertiary structures akin to proteins, classically, RNA has been targeted in a sequence-based manner rather than structure-based manner. Antisense oligonucleotides (ASOs) remain a powerful class of biologics for targeting RNA based on sequence.
Each approach is presented in a separate chapter based on individual company profiles, technology profiles and drug or drug candidate profiles.
Technology company profiles address the following aspects:
General overview (founders, foundation year, technology source, location, number of employees), main business activities
Funding history and financial situation
Technology overview
Partnering
Targets and pipeline
RNA-Targeted Drug Modalities covered by this report are:
mRNA Translation Regulation
RNA Splicing Modification
RNA Trans-Splicing
RNA Editing
Epitranscriptomics
lncRNA & regRNA
Direct RNA Targeting
The report addresses for each approach to target RNA with novel treatment modalities:
Stakeholders in the field, i.e. technology companies, pharmaceutical partners and investors
Technologies of RNA target discovery and discovery of drugs targeting RNA
RNA targets selected for drug discovery and the associated clinical indications or therapeutic areas
Preclinical and/or clinical experience with RNA-targeted novel drug modalities
Financing history and financial situation of RNA technology companies
Partnering deals (discovery and/or development collaborations, licensing, acquisitions)
Comparative assessment of technology companies based on technology validation by data, partnering and investors
What will you find in the report?
Profiles of pure-play and diversified RNA-targeted drug technology companies
Description of Major Pharma's role in the field (partnering, acquisition and investing)
Comprehensive description and analysis of emerging RNA target discovery and drugging technologies
RNA drugging technology selection and preferences of major pharma
Pharmacologic profiles of RNA-targeted novel drugs and drug candidates
Target selection, pipeline analysis and competition of drug candidates
Description and analysis of financing rounds (capital raised, investors)
Economic terms of collaboration and licensing deals
Sources of financing
Who will benefit from the report?
Venture capital, private equity and investment managers
Managers of Big Pharma venture capital firms
Financial analysts
Business development and licensing (BDL) specialists
